Hosted on MSN1mon
GSK's depemokimab gets EMA nod for asthma and nasal polypsGSK plc (LSE/NYSE ... is based on the promising results from the SWIFT and ANCHOR clinical trials. If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing ...
GSK plc announced that the European Medicines ... multi-centre phase III clinical trials. The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and ...
Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...
1-3 In asthma patients and patients with CRSwNP, these trials showed depemokimab could offer sustained inhibition of a key driver of their disease, and help achieve key clinical outcomes with a ...
GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical ... This acceptance, announced today, is based on the promising results from the SWIFT and ANCHOR clinical trials. If approved, depemokimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results